Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNP-612 in NAFLD
NCT03868566Phase 2Terminated
- Sponsor
- Sinew Pharma
- Start
- Aug 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of SNP-612 in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Sinew Pharma. Primary endpoint: Change in serum ALT at 12 weeks. Started Aug 2017; status: terminated.
02
Drugs
SNP-612
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03868566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03868566.